Proceedings of the National Academy of SciencesMicrobiologyPeer-reviewed journal article
Sp140L Is a Novel Herpesvirus Restriction Factor
Jana M. CableiD, Wiyada WongwiwatiD, Jenna C. GrabowskiiD, Robert E. WhiteiD, Micah A. LuftigiD
Abstract
Herpesviruses, including Epstein-Barr Virus (EBV) - a human oncogenic viruses and essential trigger of multiple sclerosis, must bypass host DNA sensing mechanisms to establish lifelong, latent infection. Therefore, herpesviruses encode viral proteins to disrupt key host factors involved in DNA sensing and viral restriction. The first viral latency protein expressed, EBNA-LP, is essential for transformation of naive B cells and establishment of viral gene expression, yet its role in evading host defenses remains unclear. Using single-cell RNA sequencing of EBNA-LP-Knockout (LPKO)- infected B cells, we reveal an antiviral response landscape implicating the speckled proteins as key cellular restriction factors countered by EBNA-LP. Specifically, loss of SP100 or the primate-specific SP140L reverses the restriction of LPKO, suppresses a subset of canonically interferon-stimulated genes, and restores transcription of essential latent viral genes and cellular proliferation. Notably, we also identify Sp140L as a restriction target of the herpesvirus saimiri ORF3 protein, implying a role for Sp140L in immunity to other diverse DNA viruses. This study reveals Sp140L as a restriction factor that we propose links sensing and transcriptional suppression of viral DNA to an IFN-independent innate immune response, likely relevant to all nuclear DNA viruses. Significance StatementHerpesviruses, including the oncogenic Epstein-Barr virus (EBV), are restricted by DNA sensing during initial infection and therefore encode viral proteins to antagonize key restriction factors. We found that the EBV latency protein EBNA-LP, disrupts the speckled proteins Sp100 and Sp140L - an evolutionarily recent protein with unknown function, which we find promotes an anti-viral state that suppresses cellular proliferation, characterized by high induction of cellular anti-viral genes and suppressed transcription of essential viral latency genes. Sp140L also restricts the herpesvirus saimiri, which we find antagonizes Sp140L through the viral protein ORF3. Our study therefore identifies Sp140L as a novel restriction factor of diverse herpesviruses, and likely all DNA viruses, during a critical stage of initial viral infection.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 13
- FWCI
- 4.42
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program
Laura A. Murray‐Nerger, Davide Maestri, … Benjamin E. Gewurz·PLoS PathogensPeer-reviewed·Sep 6, 2024
- A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling
Shunji Li, Yizhe Sun, … Benjamin E. Gewurz·bioRxiv·Mar 20, 2026
- Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naive B cells, and facilitates recruitment of transcription factors to the viral genome.
A. Szymula, R. D. Palermo, … R. E. White·bioRxiv·Aug 22, 2017
- Conserved Herpesvirus Protein Kinases Target SAMHD1 to Facilitate Virus Replication
- A comprehensive single cell data analysis of in lymphoblastoid cells reveals the role of Super-enhancers in maintaining EBV latency
B. Yan, C. Wang, … M. Kazemian·bioRxiv·Aug 10, 2022
- Proteomic Screening Identifies HNRNPA2B1 as an Epigenetic Repressor of Epstein-Barr Virus Reactivation
Febri Gunawan Sugiokto, Y Liu, Renfeng Li·Journal of VirologyPeer-reviewed·Jun 12, 2026